Synovus Financial Corp Purchases 2,143 Shares of The Cooper Companies, Inc. (COO)

Synovus Financial Corp raised its stake in The Cooper Companies, Inc. (NYSE:COO) by 22.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,813 shares of the medical device company’s stock after purchasing an additional 2,143 shares during the quarter. Synovus Financial Corp’s holdings in The Cooper Companies were worth $2,694,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. BB&T Investment Services Inc. raised its stake in shares of The Cooper Companies by 71.0% in the fourth quarter. BB&T Investment Services Inc. now owns 542 shares of the medical device company’s stock worth $119,000 after purchasing an additional 225 shares during the last quarter. Virtue Capital Management LLC purchased a new stake in shares of The Cooper Companies in the fourth quarter worth approximately $195,000. Conning Inc. purchased a new stake in shares of The Cooper Companies in the first quarter worth approximately $215,000. CAPROCK Group Inc. purchased a new stake in shares of The Cooper Companies in the fourth quarter worth approximately $222,000. Finally, FNY Managed Accounts LLC purchased a new stake in shares of The Cooper Companies in the fourth quarter worth approximately $217,000. 97.68% of the stock is owned by hedge funds and other institutional investors.

In other The Cooper Companies news, Director Michael Kalkstein sold 1,715 shares of the stock in a transaction on Wednesday, April 11th. The stock was sold at an average price of $221.66, for a total transaction of $380,146.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Carol R. Kaufman sold 13,362 shares of the stock in a transaction on Monday, March 12th. The shares were sold at an average price of $243.88, for a total value of $3,258,724.56. Following the transaction, the executive vice president now directly owns 59,305 shares of the company’s stock, valued at $14,463,303.40. The disclosure for this sale can be found here. Insiders have sold 51,846 shares of company stock valued at $12,549,839 over the last ninety days. 1.60% of the stock is currently owned by company insiders.



Several analysts have recently commented on COO shares. Cleveland Research downgraded The Cooper Companies from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Oppenheimer set a $265.00 price objective on The Cooper Companies and gave the stock a “hold” rating in a research note on Thursday, March 29th. Stephens reissued a “hold” rating and issued a $270.00 price objective on shares of The Cooper Companies in a research note on Friday, March 9th. Jefferies Group reissued a “buy” rating and issued a $285.00 price objective on shares of The Cooper Companies in a research note on Friday, March 9th. Finally, TheStreet downgraded The Cooper Companies from a “b” rating to a “c” rating in a research note on Thursday, March 8th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $264.18.

Shares of COO opened at $234.32 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.83 and a quick ratio of 1.61. The company has a market cap of $11.49 billion, a P/E ratio of 22.15, a price-to-earnings-growth ratio of 1.84 and a beta of 0.62. The Cooper Companies, Inc. has a 12 month low of $207.10 and a 12 month high of $260.26.

The Cooper Companies (NYSE:COO) last issued its quarterly earnings results on Thursday, March 8th. The medical device company reported $2.79 EPS for the quarter, beating the Zacks’ consensus estimate of $2.51 by $0.28. The company had revenue of $590.00 million during the quarter, compared to the consensus estimate of $583.07 million. The Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The Cooper Companies’s revenue was up 18.2% on a year-over-year basis. During the same period last year, the business posted $1.93 earnings per share. equities research analysts predict that The Cooper Companies, Inc. will post 11.82 EPS for the current year.

The Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NYSE:COO).

Institutional Ownership by Quarter for The Cooper Companies (NYSE:COO)

Receive News & Ratings for The Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply